Global RNA-based Therapies Market: Industry Outlook
The global RNA-based therapies market was values as US$90.56 billion in 2024, and is expected to reach US$ 213.54billionby 2033, growing at a CAGR of 10.0% during the forecast period 2025-2033.
The global RNA-based therapeutics market is growing due to advancements in delivery technologies, personalized medicine, and the rise of rare genetic disorders, cancers, and infectious diseases. Collaborations between pharmaceutical and biotechnology companies and investment in RNA research are driving growth. Commercial success of mRNA vaccines has boosted confidence in RNA modalities, leading to faster clinical development and broader therapeutic applications. However, challenges include high development costs, scalability issues, regulatory complexities, safety concerns, and competition from other treatment approaches. Opportunities are expanding in areas like oncology, cardiometabolic disorders, immunology, and rare diseases, supported by innovations like self-amplifying RNA and small activating RNA.
Drivers & Restraints
Driver: Rising Prevalence of Genetic and Rare Diseases
The increasing prevalence of genetic and rare diseases is driving the RNA-based therapeutics market, as these conditions often lack effective treatments and are caused by well-defined genetic mutations. RNA technologies, such as antisense oligonucleotides, small interfering RNAs, and messenger RNAs, can modulate or replace specific gene expressions, making them ideal for rare, inherited, and orphan diseases. Global awareness, improved genetic screening, and supportive regulatory frameworks are incentivizing research and development in this area. As more rare disease patients receive accurate diagnoses, demand for precision therapies is increasing, positioning RNA-based therapeutics as a transformative solution.
For instance, rare diseases affect a small number of individuals, but with over 7000 types, the global burden is significant. Approximately 300 million people live with rare diseases, often neglected and marginalized, particularly in low-income and middle-income countries.
Restraint: Complex Regulatory Pathways and Safety Concerns
The RNA-based therapeutics market faces challenges due to complex regulatory pathways and safety concerns. Regulatory agencies require extensive preclinical and clinical data to assess risks like off-target effects, immune system activation, toxicity, and potential gene modulation. This often extends development timelines and increases costs.
The novelty of some RNA platforms means limited long-term safety data, prompting cautious review by authorities and conservative prescribing by clinicians. This combination of rigorous oversight, evolving compliance requirements, and safety verification can slow product launches, deter smaller companies, and affect investor confidence, despite the science's progress.
For more details on this report - Request for Sample
Segmentation Analysis
The global RNA-based therapies market is segmented based on type, indication, end user, and region.
Type: The antisense oligonucleotides (ASO) from the type segment the expected to have 25.51% of the RNA-based Therapies market share.
The Antisense Oligonucleotides (ASO) segment is gaining popularity in the RNA-based therapeutics market due to its ability to target specific genetic mutations causing rare and untreatable diseases. ASOs offer high specificity by binding to complementary RNA sequences, allowing precise gene expression modulation. Breakthrough therapies like nusinersen and eteplirsen have demonstrated clinical efficacy and regulatory and commercial viability, encouraging further investment and pipeline expansion. Advances in backbone chemistry and delivery systems are enhancing ASO stability, tissue penetration, and safety profiles, allowing systemic administration and targeting difficult-to-reach tissues.
For instance, in November 2024, Trace Neuroscience, founded in January, raised $101 million in a series A financing round to advance its antisense oligonucleotide therapy (ASO) treatment for ALS, a condition gained awareness through the ice-bucket challenge.
Geographical Analysis
The North America global RNA-based therapies market was valued at 42.1% market share in 2024
North America's RNA-based therapeutics market is thriving due to advanced research infrastructure, robust funding, and a supportive regulatory environment. The region's RNA-focused biopharmaceutical companies, partnership with companies, academic research centers, and specialized manufacturing facilities create a robust pipeline for drug development. High adoption of genetic testing and precision medicine, along with well-established reimbursement frameworks for rare and orphan disease treatments, is fostering rapid market uptake.
For instance, in May 2025, Eli Lilly and South Korean biopharmaceutical company Rznomics have partnered to develop and commercialize novel RNA-editing therapies for sensorineural hearing loss, using Rznomics' proprietary trans-splicing ribozyme platform, a clinical-stage biopharmaceutical company.
Market –Major Players
The major players in the RNA-based Therapies market include Sarepta Therapeutics, Alnylam Pharmaceuticals, NS Pharma, Pfizer, Modern Therapeutics, Novartis, Biogen, and Novo Nordisk among others.
Key Developments
- In January 2025, Danish biotech company nverna Therapeutics, co-founded by the University of Southern Denmark and Argobio, has launched as a leading-edge RNA therapeutics company. The company aims to improve patient outcomes in severe genetic diseases, starting with a program addressing Huntington's disease.
- In September 2024, Aurora Biosynthetic, a leading RNA therapeutics manufacturing company, has launched its new end-to-end solution for Good Manufacturing Practice (GMP) production of plasmid DNA, messenger RNA, and lipid nanoparticles, marking a new era in RNA therapeutics manufacturing in the Asia-Pacific region.
Market: Scope
| Metrics | Details | |
| CAGR | 10.0% | |
| Market Size Available for Years | 2022-2033 | |
| Estimation Forecast Period | 2025-2033 | |
| Revenue Units | Value (US $Bn) | |
| Segmentation | Type | Antisense Oligonucleotides (ASO), RNA interference, CRISPR/Cas-based RNA editing system, mRNA vaccines, RNA Aptamers, Others |
| Indication | Rare Genetic Diseases, Oncology, Infectious Diseases, Neuromuscular, Others | |
| End User | Hospitals & Clinics , Research Institutes , Pharmaceutical & Biotech Companies | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and the Middle East & Africa | |
The global RNA-based therapies market report delivers a detailed analysis with 59 key tables, more than 56visually impactful figures, and 195 pages of expert insights, providing a complete view of the market landscape.
Suggestions for Related Report
For more pharmaceuticals-related reports, please click here
